Company intelligence / Profile preview

Vectans Pharma

Ownership: Private
Employees: ~49
Development stage: Commercial

Overview

Vectans Pharma specializes in optimizing existing treatments and developing novel therapeutics for unmet medical needs, particularly within oral pathology. Its proprietary Lauriad® technology enables targeted delivery via mucoadhesive buccal tablets. The company has commercialized at least two "best-in-disease" products across major global markets and continues to expand its pipeline with additional programs focused on anti-infectives and supportive care.

Therapeutic areas: OtherInfectious Diseases
Modalities: Mucoadhesive buccal tablet technology (Lauriad®)
Industry: Biotech

Drug pipeline

16 assets

LAU-OralCare

Preclinical

15 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Vectans Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vectans Pharma.

Explore the full profile